NO995231L - Terapeutisk behandling av hudlidelser - Google Patents

Terapeutisk behandling av hudlidelser

Info

Publication number
NO995231L
NO995231L NO995231A NO995231A NO995231L NO 995231 L NO995231 L NO 995231L NO 995231 A NO995231 A NO 995231A NO 995231 A NO995231 A NO 995231A NO 995231 L NO995231 L NO 995231L
Authority
NO
Norway
Prior art keywords
therapeutic treatment
skin disorders
vascular permeability
dermatitis
phemigoid
Prior art date
Application number
NO995231A
Other languages
English (en)
Norwegian (no)
Other versions
NO995231D0 (no
Inventor
Michael R Jirousek
Lawrence E Stramm
Louis Vignati
Douglas K Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO995231D0 publication Critical patent/NO995231D0/no
Publication of NO995231L publication Critical patent/NO995231L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
NO995231A 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser NO995231L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4443197P 1997-04-30 1997-04-30
PCT/US1998/007808 WO1998048795A1 (en) 1997-04-30 1998-04-21 Therapeutic treatment for skin disorders

Publications (2)

Publication Number Publication Date
NO995231D0 NO995231D0 (no) 1999-10-26
NO995231L true NO995231L (no) 1999-12-27

Family

ID=21932346

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995231A NO995231L (no) 1997-04-30 1999-10-26 Terapeutisk behandling av hudlidelser

Country Status (16)

Country Link
US (1) US6093740A (id)
EP (1) EP0903145A3 (id)
JP (1) JP2002501501A (id)
KR (1) KR20010020381A (id)
CN (1) CN1259866A (id)
AU (1) AU7131898A (id)
BR (1) BR9809343A (id)
CA (1) CA2289257A1 (id)
EA (1) EA199900987A1 (id)
HU (1) HUP0002836A2 (id)
ID (1) ID23528A (id)
IL (1) IL132520A0 (id)
NO (1) NO995231L (id)
PL (1) PL336760A1 (id)
TR (1) TR199902682T2 (id)
WO (1) WO1998048795A1 (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1579871A1 (en) * 1998-12-22 2005-09-28 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
DK1905457T3 (da) * 1999-12-22 2012-05-29 Scripps Research Inst Farmaceutiske sammensætninger omfattende Src og/eller Yes samt anvendelse deraf
JP3429297B1 (ja) 2002-02-20 2003-07-22 株式会社ノエビア 皮膚外用剤
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20070032479A1 (en) * 2003-12-03 2007-02-08 Leventer Steven M Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
DE102004019413A1 (de) * 2004-04-19 2005-11-24 Phenos Gmbh Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten
JP2009523807A (ja) 2006-01-18 2009-06-25 ザ ジェネラル ホスピタル コーポレイション リンパ機能を高める方法
US7455447B2 (en) * 2006-05-19 2008-11-25 Mediatek Inc. Method and apparatus for a portable device
CN101380317B (zh) * 2007-09-07 2010-12-08 英属开曼群岛商安盛开发药物股份有限公司 减缓搔痒症的药学组合物
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
US20180185259A1 (en) * 2016-12-19 2018-07-05 Chromaderm, Inc. Methods of treating hyperpigmentation disorders
CA3255435A1 (en) 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations allowing the use of a PK inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
BR9404830A (pt) * 1993-12-07 1995-08-08 Lilly Co Eli Composto e processo para sua preparação
KR100340159B1 (ko) * 1993-12-07 2002-11-23 일라이 릴리 앤드 캄파니 단백질키나제c억제제
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
ES2122764T3 (es) * 1995-11-20 1998-12-16 Lilly Co Eli Inhibidor de la proteina quinasa c.
CA2253608A1 (en) * 1996-05-01 1997-11-06 Louis Vignati Therapeutic treatment for vegf related diseases
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту

Also Published As

Publication number Publication date
NO995231D0 (no) 1999-10-26
US6093740A (en) 2000-07-25
PL336760A1 (en) 2000-07-17
AU7131898A (en) 1998-11-24
TR199902682T2 (xx) 2000-05-22
BR9809343A (pt) 2000-07-04
ID23528A (id) 2000-04-27
CA2289257A1 (en) 1998-11-05
JP2002501501A (ja) 2002-01-15
EA199900987A1 (ru) 2000-08-28
EP0903145A2 (en) 1999-03-24
CN1259866A (zh) 2000-07-12
WO1998048795A1 (en) 1998-11-05
IL132520A0 (en) 2001-03-19
HUP0002836A2 (hu) 2001-02-28
KR20010020381A (ko) 2001-03-15
EP0903145A3 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
WO2002036072A3 (en) Method for short-term and long-term drug dosimetry
GB9917406D0 (en) Compounds
GB0118238D0 (en) Medicaments
GB0101577D0 (en) Compounds
GB0112836D0 (en) Medicaments
CA2253613A1 (en) Therapeutic treatment for vegf related occular diseases
AP1806A (en) The use of a high dosage regimen of amoxycillin and potassium chavulate for the treatment of bacterial infections.
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
AU2003273182A1 (en) Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
EP1631297A4 (en) TREATMENT OF IMMUNOSTIC DISEASES WITH ACTIVE VITAMIN D COMPOUNDS ALONE OR IN COMBINATION WITH OTHER THERAPEUTICS
EP0903145A3 (en) Pharmaceutical composition for skin disorders
AU3476397A (en) Therapeutic treatment for cardiovascular diseases
SE9300971D0 (sv) Hudvaardskomposition
TR200102512T2 (tr) Tüm ruhsal bozukluklar, adaptasyon bozuklukları ve çeşitli kaygı-depresyon bozukluklarının tedavisinde ya da önlenmesinde yararlı tıbbi ürünlerin hazırlanması için saredutan ve onun farmasötik olarak kabul edilebilir tuzlarının kullanımı.
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
WO2004030623A3 (en) Nitroxide radioprotector formulations and methods of use
EP0940141A3 (en) Use of PKC inhibitors for the manufacture of a medicament for the treatment of cytomegalovirus infection
EP0940143A3 (en) Use of PKC-inhibitors for the manufacture of a medicament for the treatment of asthma
WO2002041841A3 (en) Compositions for adhesion prevention
WO2004103985A3 (en) Derivatives of fusarochromanone as therapeutic agents
AU2450900A (en) Therapeutic nucleoside compound
HK1089385A (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application